LENZ Therapeutics (LENZ), Verve Therapeutics (VERV), Prime Medicine (PRME), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), and CRISPR Therapeutics (CRSP) were also among notable decliners.

Verve Therapeutics has started dosing patients ... in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing.

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

This method contrasts with CRISPR–Cas9 ... such as Intellia Therapeutics have made strides in addressing toxicity in delivery systems. When safety concerns arose with VERVE-101, Verve was ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st ... In the field of cardiovascular health, Verve Therapeutics is developing VERVE-101, a base-editing therapy for familial ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last released its quarterly earnings data on Tuesday, November 5th.